We’re thrilled to announce the appointment of Kim Tun Lau as Oppimi new Board Member.
“We are excited to announce the addition of this very accomplished healthcare and pharmaceutical industries leader to Oppimi,” said Ervin Ukaj, Chairman and Chief Executive Officer of Oppimi. “His guidance and expertise will be instrumental as we continue the development of our supportive digital ecosystem for learning disabilities and new product pipeline.”
Mister Kim Tun Lau is a key founding member of JIDA pharmaceutical and Jiwa Bio-Pharm Holdings. He has more than 15 years experience in the healthcare industry and pharma sector for China market. As CEO of JIDA for the last 15 years, he expended the group from ground to a regional pharmaceutical company of 2,000 employees and a revenue of RMB 1.5 Billion. He is also Vice Chairman and CEO of Jiwa; Mr Kim Tun Lau is a very active member of theses industries.
Oppimi supports test and treatment for children affected by learning disabilities with innovative diagnosis and therapy digital products through AI and Gamification. We are using AI for creating clinically-validated Digital Health Products for diagnosing and treating children that are affected by learning disabilities.
Ai is changing drastically how health is approching LDs, and we are enbracing big data as core. Oppimi’s algorithms, based on machine learning techniques, are able to monitor patient’s advancements and suggest new tasks for optimizing the training results. We are providing a full ecosystem that connects learning disabilities specialists, teachers and children’s parents.
Children have access from their home, while parents can consult therapy advancement and doctors, high-quality analytics. We strive to test our products at multiple levels including with a strong methodology and structured specialists validations. Then the game itself is build in respect of fair game rules without violence and in respect of clean game mechanics.